Page 27 - Read Online
P. 27

Battaglin et al. J Cancer Metastasis Treat 2018;4:12  I  http://dx.doi.org/10.20517/2394-4722.2018.04                      Page 23 of 25

                   Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L,
                   Velculescu VE. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015;526:263-7.
               138  Lee MS, Kopetz S. Current and future approaches to target the epidermal growth factor receptor and its downstream signaling in
                   metastatic colorectal cancer. Clin Colorectal Cancer 2015;14:203-18.
               139  Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C,
                   Tamburini E, Capone I, Volpi C, Milione M,  Di Maio M, Fontanini G, De Braud FG, Falcone A, Pietrantonio F. Dissecting primary
                   resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): a case-control study. J Clin Oncol 2017;35:abstr
                   11508.
               140  Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta
                   E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate
                   AJ, Bardelli A, Corcoran RB. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov
                   2016;6:147-53.
               141  Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from
                   heterogeneity to convergent evolution. Cancer Discov 2014;4:1269-80.
               142  Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri
                   S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular
                   domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012;18:221-3.
               143  Esposito C, Rachiglio AM, La Porta ML, Sacco A, Roma C, Iannaccone A, Tatangelo F, Forgione L, Pasquale R, Barbaro A, Botti G,
                   Ciardiello F, Normanno N. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before
                   exposure to EGFR monoclonal antibodies. Cancer Biol Ther 2013;14:1143-6.
               144  Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, Binder M. Functional dissection of the epidermal growth factor
                   receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 2012;14:1023-31.
               145  Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan
                   E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell
                   J, Bardelli A, Montagut C. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin
                   Cancer Res 2015;21:2157-66.
               146  Price TJ, Newhall K, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AV, Thomas A, Tjulandin S, Boedigheimer M, Zhang K, Sidhu
                   R, Murugappan S. Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: panitumumab
                   (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol
                   2015;33:abstr740.
               147  Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di
                   Nicolantonio F, Nering R, Bardelli A. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers
                   harboring EGFR extracellular domain mutations. Sci Transl Med 2016;8:324ra314.
               148  Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved
                   NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J. Safety and activity of
                   the first-in-class Sym004 Anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov 2015;5:598-609.
               149  Cidon EU, Alonso P, Masters B. Markers of response to antiangiogenic therapies in colorectal cancer: where are we now and what
                   should be next? Clin Med Insights Oncol 2016;10:41-55.
               150  Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O’Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ.
                   Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with
                   bevacizumab. Clin Cancer Res 2012;18:6384-91.
               151  Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Alì G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanotto M,
                   Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, Melisi D. Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal
                   cancer patients. Clin Cancer Res 2017;23:4312-22.
               152  Paiva TF Jr, de Jesus VH, Marques RA, da Costa AA, de Macedo MP, Peresi PM, Damascena A, Rossi BM, Begnami MD, de Lima VC.
                   Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
                   BMC Cancer 2015;15:643.
               153  US National Library of Medicine. A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer. Identifier: NCT
                   NCT03035253. Available from: https://clinicaltrials.gov/ct2/show/NCT03035253?term=bispecific+oncomed&rank=1 [Last accessed on
                   17 Jan 2018]
               154  Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M,
                   Barat A, Klinger R, Fender B, O’Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne
                   AT, van der Flier LG, Gallagher WM, Postel R. Apelin: a putative novel predictive biomarker for bevacizumab response in colorectal
                   cancer. Oncotarget 2017;8:42949-61.
               155  Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T,
                   Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and
                   protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a
                   retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16:937-48.
               156  Wirapati P, Pomella V, Vandenbosch B, Kerr P, Maiello E, Jeffery GM, Curca ROD, Karthaus M, Bridgewater JA, Mihailov AC, Kiss I,
                   Merino S, McKendrick JJ, Saridaki Z, Sagaert XJA, Tejpar S. Velour trial biomarkers update: impact of RAS, BRAF, and sidedness on
   22   23   24   25   26   27   28   29   30   31   32